Eurofins Scientific Se · EURONEXT:ERF
Eurofins Scientific — Investor Day (October 2026)
27 slides from Eurofins Scientific's investor day presentation, Oct 23, 2026
Slide 1: 2026 European Investor Day
CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2026. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific S.E. and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on
Slide 3: CEO Presentation
CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2026. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af
Slide 4: Eurofins: The World Leader in Testing for Life
Eurofins: The World Leader in Testing for Life Key Figures 35+ years of value creation • Long-term track record of turning investments into growth, productivity, margin expansion and Return on Capital Employed 950+ laboratories 450,000,000+ • Competitive advantages based on scale and one-of-a-kind f
Slide 5: Strong secular growth drivers across all Eurofins activities
Strong secular growth drivers across all Eurofins activities Long-term objective: 6.5% p.a. average organic growth Revenue share Organic growth Activities in FY 2025 Growth drivers outlook • Rising awareness and demand for food safety & quality • Food and Feed Testing and contamination & pollution i
Slide 6: Late stages of a transformative five-year investment programme, running to 2027
Eurofins is now in the late stages of a transformative five- year investment programme, running to 2027 Major investment categories moderating as programme progresses (€m) 2022 2023 2024 2025 H1 2026 Major initiatives Progress as of 2026 Leasehold improvements, machinery Investments in laboratory ne
Slide 7: Laboratory investments are delivering state of the art sites
Laboratory investments are delivering state of the art sites, aligned with strategic priorities Further planned additions to owned sites in Showcasing key strategic projects completed in H1 2026 2026-2028 Environment Testing BioPharma CDMO Amersfoort, The Netherlands Mississauga, Canada 8,743 m² 13,
Slide 8: One-of-a-kind 'hub and spoke' laboratory network infrastructure
One-of-a-kind ‘hub and spoke’ laboratory network infrastructure is our platform for market leadership Example: North America Food & Feed Testing Hub laboratories NUTRITION Competence centres concentrate more specialised testing demands CONTAMINANTS • Facilitates greater volume of samples than compet
Slide 9: Lower capex needs and automation benefits in completed hub and spoke networks
2025 Investor Days showed the lower capex needs and automation benefits in completed hub and spoke networks Example: North America Food & Feed Testing Hubs 400000000 60% increase in 2020 capex increase due 350000000 350000000 revenues/FTE 15% 270000 300000000 to Madison investment 300000000 2016-25
Slide 10: IT costs are gradually reducing as key projects complete
IT costs are gradually reducing as key infrastructure and laboratory solutions projects complete 2025 total IT investment: c.€500m, c.7% of revenues 2025 IT capex: €100m, 1.4% of revenues Project milestones being delivered: Looking forward: Eurofins’ unique position BioPharma and North America Envir
Slide 11: Capital deployed since 2019 has delivered significant value creation
Capital deployed since 2019 has delivered significant value creation Evolution of Eurofins’ returns Incremental 20191 2023 2024 2025 return on capital2 2019-2025 Adjusted EBITAS (m€) 574 842 1,017 1,079 +505 Eurofins has significantly expanded returns during the current Capital Employed (m€) 6,304 8
Slide 12: Profitability and cash flow at, or approaching, the 2027 objectives
Profitability and cash flow are at, or approaching the 2027 objectives even before key initiatives are complete Adjusted EBITDA margin on SDI at EBITDA level as % of total Cash Conversion, total revenues revenues FCFF/reported EBITDA FY 2027 objective: FY 2027 24% objective: above 50% 23.7% 0.9% exc
Slide 13: Strong profitability and cash flow support M&A and shareholder returns
Strong profitability and cash flow support both ongoing M&A and shareholder returns CAGR 2023 2024 2025 2023-25 Reported Revenues (m€) 6,515 6,951 7,296 6% Reported EBITDA (m€) 1,234 1,439 1,561 12% Cash flow: Cash Net cash provided by operating activities 1,018 1,319 1,399 17% Growth in free cash g
Slide 14: Element - building on strong market positions
Element - building on strong market positions where Eurofins has focus and network effects Example: Broader reach of combined North America Environment Testing laboratory footprint Aligned with ongoing capital allocation focus on core testing for life capabilities • Acquired operations include a net
Slide 15: Mid-term objectives: an even more profitable and cash generative financial profile
Mid-term objectives: an even more profitable and cash generative financial profile • Mid-single-digit organic growth target for 2027 Revenue growth • Long-term average organic growth target of 6.5% p.a. and potential average revenues from acquisitions of €250m p.a. over the period consolidated at mi
Slide 16: Summary
Summary Eurofins’ five-year investment programme is creating a unique, fully digitalised network of laboratories, supporting long-term market leadership Investment coming down from peak as key projects complete, delivering a well-invested state of the art network at the end of 2027 On track for mid-
Slide 17: Environment Testing Europe
CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2026. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af
Slide 18: Eurofins' Environmental Testing offering is the most comprehensive in the market
Eurofins’ Environmental Testing offering is the most comprehensive in the market Pollution Built Energy & Specialty Water Testing Air Testing Environment Minerals Testing Water Testing Contaminated Sites Building Materials Air Monitoring BioFuels Specialty Testing • Drinking water • Soil • Asbestos
Slide 19: Customer profile & segmentation; Competitors
Customer profile & segmentation Consulting & Industry Governments Engineering Customers1 & Contracts Multi-Vertical Expertise Global Players European, National, Local • Utilities • Infrastructure • Energy & Power • Real Estate • Chemicals • Transportation + Regional and Local Customers • Mining • Wa
Slide 20: Environment Testing Europe market overview
Environment Testing Europe market overview Europe Environment Testing Market segmentation example - France Mix of end markets Diversified customer mix Government 10 largest 13% 25% customers Industry 33% Direct Small local ~€2.5B~ >10,600 players market Customers 61% 14% Engineering Remainder of Cus
Slide 21: A unique European hub and spoke network, evolving from expansion to optimisation
Strategy – a unique European Hub and Spoke network, evolving from expansion to optimisation Network Hub Hubs added or 21 >130 >6,800 scaled since 2022 Countries Laboratories Staff European Network Hubs by specialty Contaminated Sites Drinking Water & Remediation & Wastewater Amersfoort, NL * Amersfo
Slide 22: Europe PFAS testing remains a major long-term growth opportunity
Europe PFAS testing remains a major long-term growth opportunity for Eurofins PFAS in Europe: a large and growing Leveraging Eurofins’ global expertise Europe on the rapid growth trajectory testing market of >€100m in 2025 for continued growth in Europe already seen in North America • PFAS continues
Slide 23: Applying the PFAS playbook to the microplastics opportunity
Looking ahead – applying the PFAS playbook to the early-stage, developing microplastics opportunity Microplastics Testing: an emerging high- Eurofins has moved quickly to establish Microplastics testing volumes starting to growth market leadership as the market develops accelerate • Small fragments
Slide 24: Converting scale into customer value through integrated logistics
Strategy – Converting scale into customer value and network efficiency through integrated logistics Differentiated platform, combining Benelux case study: Proven model in a critical customer service differentiator, leading scale with highly integrated with the opportunity to replicate across the ent
Slide 25: Building deeper process automation and technology adoption into new facilities
Strategy – building deeper process automation and technology adoption into new facilities Amersfoort: purpose-built for end-to-end automation One seamless automated workflow, connecting physical processes, digital orchestration and AI integration: Sub-sampling & storage Pre-treatment Measurement aut
Slide 26: Emerging opportunity in multinational account growth
Emerging opportunity – multinational account growth is accelerating demand for coordinated European solutions Eurofins’ core strengths are strongly aligned with the needs of this high-growth segment: Top-10 Global Leading Global Industry Leading Environmental Consultant NGO Consortium • Began as a r
Slide 27: Summary
Summary Market Leadership - Eurofins is the #1 environmental testing provider in Europe (and globally), with unmatched breadth across all key matrices and industry sectors Sustained GDP+ growth profile with attractive market structure and diverse customer base Scalable and evolving operating platfor